Journal of Clinical and Diagnostic Research (Jun 2020)
Evaluation of N-Terminal pro B-Type Natriuretic Peptide (NT-proBNP) Levels with Co‑morbidity Factors as a Threshold Concept of Heart Dysfunction Progress
Abstract
ABSTRACT Introduction: Ischemic Heart Diseases (IHD) is one of the most common causes of death worldwide. Myocardial impairment is an imbalance between coronary blood flow and myocardial needs which result in circulatory changes. Cardiovascular Disease (CVDs) (including IHD and hypertensive heart disease) accounts for 31% of total world mortality; it has been estimated that 17.9 million people died from CVDs in 2016. IHD alone is the cause of 7.2 million deaths equalling to 12.6% of the total (World Health Organisation, 2017). Aim: To examine the N-Terminal proB-type Natriuretic Peptide (NT-proBNP) levels and their association with some co-morbidity factors in the IHD patients. Materials and Methods: The present case control study comprises a group of 90 subject with IHD which were selected from Cardiac Care Unit (CCU), Al Hussein Teaching Medical City, Kerbala, Iraq. Quantitative determination of the biochemical markers was performed; Chemiluminescence Immunoassay (CLIA) was used for serum NT-proBNP levels. Significant differences in continuous variables among the parameters were confirmed through analytical statistical tests (ANOVA). Results: Mean NT-proBNP levels in male patients with IHD (mean age 53.76 year) were 249.89 pg/mL as compared to 62.35 pg/mL in control subjects. Increased level of NT-proBNP was independently associated significantly with patients being hypertensive, having insulin resistance and smoking with p-values <0.01. Conclusion: Patients with elevated NT-proBNP levels may be a good indicator for the severity of heart diseases, but many offending agents might interfere with the progress of such cases. Offending factors should be kept under consideration while evaluating the correlation of NT-proBNP level and history of these patients.
Keywords
